.

Blog Post

Keeping the Money Is the Fraud: Three DOJ Settlements in One Week Target Retained Overpayments

October 19, 2026 – FCA Now

by Chris DeLong, Matthew Gillespie, and Elise Brazelton

Download as a PDF

Share this page

In the span of one week, the United States Department of Justice (DOJ) announced three False Claims Act (FCA) settlements built on the same theory: each organization allegedly had reason to know it had been overpaid and kept the money anyway.

  • Signal Diagnostics LLC agreed to pay $20.5 million (September 30, 2026) for allegedly avoiding repayment of COVID-19 testing claims to the Health Resources & Services Administration’s (HRSA’s) Uninsured Program that its own audit had flagged as ineligible.
  • Independence Blue Cross agreed to pay $22.5 million (September 30, 2026) for allegedly ignoring chart reviews that failed to support Medicare Advantage diagnosis codes it had already submitted.
  • AIDS Healthcare Foundation agreed to pay $1.44 million (October 6, 2026) for allegedly failing to investigate and delete unsupported Medicare Advantage diagnosis codes.

These settlements, brought in the context of DOJ’s ongoing emphasis on healthcare fraud enforcement, underscore that DOJ continues to aggressively enforce “reverse false claims” actions.

In Each Case, the Alleged Fraud Came After the Organization Had Reason to Know of Improper Payment

Signal Diagnostics. Signal billed HRSA’s COVID-19 Uninsured Program for testing and specimen collection between October 2020 and March 2022. According to the government, Signal began an internal audit around January 2022 and “determined that it had submitted claims to the Uninsured Program that were ineligible” because the patients had insurance. The government alleges that Signal “continued to conduct its audit” through May 2023 and, during that period, “knowingly and improperly avoided obligations to repay HRSA for overpayments.” (DOJ release.)

Independence Blue Cross. For payment years 2017 through 2021, IBX ran a chart review program in which nurse reviewers “identified all medical conditions that the charts supported.” IBX used the results of its chart reviews to identify instances where IBX could seek additional payments from CMS, but when those reviews did not support codes IBX had already submitted, the government alleges, “IBX did not delete or withdraw those diagnosis codes, which would have required IBX to reimburse CMS.” The government also alleges IBX “falsely certified in writing to CMS that the data was accurate and truthful.” A former IBX employee filed the qui tam and will receive $3,825,000. United States ex rel. Crawford v. Independence Blue Cross, No. 20-cv-5818 (E.D. Pa.). (DOJ release.)

AIDS Healthcare Foundation. AHF’s managed care division ran Medicare Advantage special-needs plans for HIV patients. The government alleges that, “for payment years 2017 to 2023,” AHF “failed to timely investigate and delete diagnosis codes that were either inaccurate or not documented in medical records.” A former AHF risk-adjustment coder filed the qui tam and will receive $259,200. United States ex rel. Irons v. AIDS Healthcare Foundation, No. 23-cv-2160 (C.D. Cal.). (DOJ release.)

All three resolutions are settlements of allegations. None involved a determination of liability. Signal’s matter, notably, came without a relator: the government built the case on its own.

The FCA Treats a Knowingly Retained Overpayment as a Reverse False Claim

The FCA’s reverse-false-claims provision imposes liability on anyone who “knowingly conceals or knowingly and improperly avoids or decreases an obligation to pay or transmit money or property to the Government.” 31 U.S.C. § 3729(a)(1)(G). The statute defines “obligation” to include a duty arising “from the retention of any overpayment.” Id. § 3729(b)(3). Submission of a false statement is not required. Knowingly keeping the money is enough.

For Medicare and Medicaid, Congress added a deadline. A provider, supplier, or Medicare Advantage organization must report and return an overpayment within 60 days after it is “identified,” and an overpayment kept past that date “is an obligation” for FCA purposes. 42 U.S.C. § 1320a-7k(d).

CMS’s current regulations, effective January 1, 2025, tie “identified” to the FCA’s knowledge standard. A Medicare Advantage (MA) organization “has identified an overpayment when the MA organization knowingly receives or retains an overpayment.” 42 C.F.R. § 422.326(c). For Parts A and B, the rule also suspends the 60-day deadline for up to 180 days while a provider conducts a timely, good-faith investigation into related overpayments. 42 C.F.R. § 401.305(b)(3)(ii).

Two features of these settlements stand out against that framework:

  • The 60-day statute is not the only trigger. Signal’s overpayments came from an HRSA pandemic program, not Medicare or Medicaid. The FCA’s definition of “obligation” reaches “the retention of any overpayment” all the same. Government contractors face the same exposure: the Federal Acquisition Regulation’s (FAR’s) Prompt Payment clause requires a contractor that “becomes aware” of an overpayment to remit it and notify the contracting officer. FAR 52.232-25(d).
  • An open-ended audit is not a safe harbor. The 2025 rule gives Part A and B providers up to 180 days to investigate. The government alleges Signal audited for roughly 16 months. IBX and AHF allegedly failed to act on investigation findings for years. Some courts have rejected the idea that the clock waits for a final number: in Kane v. Healthfirst, the Southern District of New York held that the clock starts when a provider is “put on notice of a potential overpayment.” United States ex rel. Kane v. Healthfirst, Inc., 120 F. Supp. 3d 370, 388 (S.D.N.Y. 2015).

The 2025 rule is friendlier to providers in one respect: by adopting the FCA’s knowledge standard, it removed liability for mere negligence in identifying overpayments. Most of the conduct in these settlements predates that rule. But the allegations here arguably go beyond negligence: in all three cases, the organization’s own audit or chart review allegedly surfaced the problem.

Treat Audit Findings as the Start of a Repayment Clock

These settlements give compliance teams a concrete checklist:

  1. Start the clock when the audit finds a problem, not when the audit ends. Document the date an internal review first points to an overpayment. Medicare Part A and B providers should track the 180-day investigation window from that date.
  2. Scope the investigation before it starts. Set a defined lookback period, a sampling method, and an end date. An audit with no end date invites the allegation that the organization chose to keep the overpaid money.
  3. Repay what you know while you quantify the rest. Returning any confirmed amount early limits the “knowingly retained” exposure while the broader review continues.
  4. Act on both sides of a chart review. For MA organizations, a chart review that identifies codes to be added should also identify codes without support that must be deleted.
  5. Look beyond Medicare. Grant recipients, pandemic-program participants, and government contractors carry the same obligation under the FCA’s definition of “obligation” and, for federal contractors, under FAR 52.232-25(d).
  6. Assume an employee is watching. Two of the three cases began as qui tams filed by former employees, including a risk-adjustment coder. The people who run the audit are the most likely relators.

For more on how and when to approach the government, see our earlier post, FCA Basics: Government Investigations and Self-Disclosure.

Fix the Refund Process Before a Relator Tests It

DOJ’s message is simple: an overpayment becomes FCA exposure the day an organization knows about it and chooses not to act. Organizations that receive federal funds should review their audit and refund protocols now, with a defined investigation timeline and a decision-maker accountable for repayment.

Firm Highlights

Insights

Minnesota Consumer-Fraud Enforcement: Disclaimers Won’t Cure Deception, and Penalties Can Add Up

Misleading advertising claims can lead to costly consequences. In State of Minnesota ex rel. Ellison v. Wall & Associates, Inc., No. A25-2064, 2026 WL 3118291 (Minn. App. Oct. 19, 2026), the Minnesota Court of Appeals recently affirmed a bench trial verdict against a tax-relief company and two executives for violations of the Minnesota Consumer Fraud Act (“MCFA”) and the Minnesota Deceptive Trade Practices Act (“MDTPA”). The decision, which affirmed a substantial restitution and civil penalty judgment, underscores the broad power of the Minnesota Attorney General to act against deceptive sales practices. The decision also offers practical lessons for businesses seeking to reduce liability risks in consumer-facing communications. Background Wall & Associates (“W&A”), a Virginia-based tax-relief company, marketed assistance to taxpayers seeking relief from outstanding federal and state tax liabilities, often with offers in compromise—agreements to settle tax liabilities for less than the amount owed. In its extensive advertising campaigns, W&A represented that its average client received a 90% reduction in their tax debt, that it was a local company with Minnesota offices, that it provided legal services, and that it would “Solve ALL Tax Problems.” In reality, W&A’s promises bore little resemblance to what many clients received. Most of W&A’s clients saw just a 9.5% reduction in federal tax debt and 1.2% in state tax debt. W&A had no permanent Minnesota offices. And W&A provided neither legal representation nor assistance with filing tax returns—those services required referrals to separate firms for an additional fee. All the while, W&A clients paid upfront and recurring fees, including during periods when W&A did no work on their cases. Minnesota Attorney General Keith Ellison sued W&A, its founder and owner Ernest Kenneth Wall, and its president and CEO Patrick Mark Yates, alleging violations of, among other laws, the MCFA and the MDTPA. Following a 12-day bench trial, the district court determined that W&A violated the MCFA and MDTPA through its false and embellished advertising. The district court also held Wall and Yates individually liable for those violations because they directed, participated in, and acquiesced in the violations. The district court ordered injunctive relief, $2.7 million in restitution (with Wall and Yates jointly and severally liable for $1.3 million), and civil penalties of $786,517 against W&A, $415,500 against Wall, and $207,750 against Yates. The district court also awarded over $2.5 million in attorneys’ fees and costs to the state. W&A, Wall, and Yates appealed to the Minnesota Court of Appeals, which affirmed the district court’s decision on October 19, 2026. Although W&A, Wall, and Yates challenged the judgment on numerous grounds, several highlights of the decision provide important takeaways for consumer-facing businesses. Individual Reliance Is Not Required for Statutory Liability W&A argued that Attorney General Ellison had to prove a causal nexus between each violation of the MCFA and MDTPA and the injury to a particular consumer to establish liability. In W&A’s view, this required proof that each injured consumer had personally relied on W&A’s false representation. The Court of Appeals rejected this argument based on the MCFA’s and MDTPA’s plain language, which requires no proof of actual deception or confusion by consumers. The Court of Appeals finally pointed to the Minnesota Supreme Court’s decision in State v. Minnesota School of Business, Inc., which held that when a defendant’s misrepresentations are directed at and affected “a broad group of consumers, proof of direct individual reliance is not required to establish a causal nexus between MCFA violations and the harm suffered by consumers.” 935 N.W.2d 124, 135 (Minn. 2019). The Court of Appeals affirmed, however, that a causal nexus is necessary to support an award of damages under the MCFA and MDTPA. In making that determination, district courts look to various factors, including whether the misrepresentations were “longstanding, pervasive, and widespread in communications directed to consumers,” whether the seller intended and understood that consumers would rely on the misrepresentations, and whether the information was of a kind on which consumers would typically rely. The Court of Appeals’ decision continues Minnesota School of Business’s broad interpretation of liability under the MCFA and the MDTPA. Coordinated marketing campaigns to a “broad group of consumers” may expose businesses to MCFA and MDTPA liability without customer-by-customer proof of injury. That said, a causal nexus remains an element of an MCFA and MDTPA claim, and businesses involved in litigation should build a clear record at trial and on appeal showing how each of the relevant factors bears on the causal-nexus inquiry. Contractual Disclaimers Are Not an Automatic Defense to a Misleading Pitch W&A next argued that disclaimers in its client contracts prevented consumers from claiming they had been misled by its advertising. Reiterating that individual reliance is not required under the MCFA and MDTPA, the Court of Appeals held that a contractual disclaimer does not necessarily defeat a claim based on a conflicting oral representation. And on the facts of this case, the Court of Appeals agreed with the district court that W&A’s contractual disclaimers were insufficient given the extensive misrepresentations by W&A and the unequal bargaining power between it and its customers. This holding confirms that contractual disclaimers are not a cure-all for misleading advertising or sales practices. Businesses should review the entire customer journey, including pre-contract representations, as those representations may survive a contractual disclaimer to the contrary. And if faced with litigation, businesses should build a strong record, both at trial and on appeal, showing why any disclaimer is effective in context. The State Has Broad Authority to Seek Restitution W&A also challenged Attorney General Ellison’s authority to seek restitution under the state’s parens patriae authority to protect residents’ collective interests, arguing that injury to only 228 Minnesotans did not affect a sufficiently substantial segment of the population. The Court of Appeals rejected a simple headcount approach, instead explaining that the state had a legitimate interest in protecting residents’ economic well-being as a whole. In any event, the Court of Appeals held that if restitution was not appropriate under the state’s parens patriae authority, then it would still be appropriate under the Attorney General’s enforcement powers under Minn. Stat. § 8.31. The decision reinforces that the broader and more sustained the deceptive advertising, the stronger the case for restitution to protect Minnesotans’ economic interests. Civil Penalties Accrue Per Violation, Not Per Defendant The Court of Appeals finally rejected W&A’s claim that the Attorney General’s enforcement powers under Minn. Stat. § 8.31 permit only civil penalties of up to $25,000 for each defendant. Rather, the Court of Appeals explained that penalties are limited to $25,000 per violation. Multiple violations can therefore produce substantially greater penalties. The Court of Appeals also rejected the argument that restitution made penalties unnecessary: repaying consumers does not eliminate the need to address gains from deceptive conduct and deter future violations. Final Takeaways Align every consumer-facing communication. Broad and extensive marketing campaigns can expose businesses to stronger enforcement standards under the MCFA and MDTPA, making it critical that consumer communications remain accurate and consistent from the first advertisement through the final sale. Plan for layered enforcement exposure. Penalties under the MCFA and MDTPA can add up quickly: W&A, Wall, and Yates ultimately faced more than $6 million in civil penalties, restitution, and attorneys’ fees. The decision continues a line of Minnesota cases recognizing the Attorney General’s broad consumer-protection authority. Details matter. Although the Attorney General’s enforcement power is broad, it is not boundless. As the Court of Appeals explained, issues of causation, the effectiveness of contractual disclaimers, and the availability of restitution and civil penalties all turn on the specific facts of the case. Effective advocacy at trial and on appeal is critical to developing the facts relevant to liability and damages.